TY - JOUR
T1 - A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection
AU - Opravil, Milos
AU - Hirschel, Bernard
AU - Lazzarin, Adriano
AU - Furrer, Hansjakob
AU - Chave, Jean Philippe
AU - Yerly, Sabine
AU - Bisset, Leslie R.
AU - Fischer, Marek
AU - Vernazza, Pietro
AU - Bernasconi, Enos
AU - Battegay, Manuel
AU - Ledergerber, Bruno
AU - Günthard, Huldrych
AU - Howe, Colin
AU - Weber, Rainer
AU - Perrin, Luc
PY - 2002/5/1
Y1 - 2002/5/1
N2 - This randomized study evaluated the efficacy and tolerability of continued treatment with protease inhibitor plus nucleoside-analogue combination regimens (n = 79) or a change to the simplified regimen of abacavir-lamivudine-zidovudine (n = 84) in patients with suppressed human immunodeficiency virus type 1 (HIV-1) RNA for ≥ 6 months who did not have the reverse transcriptase 215 mutation. After a median follow-up of 84 weeks, virologic failure was 6% in the continuation and 15% in the simplified group (P = .081). Previous zidovudine monotherapy or dual therapy and archived reverse transcriptase resistance mutations in HIV-1 DNA at baseline were significant predictors of failure. Study treatment was discontinued because of adverse events in 20% of the continuation and 7% of the simplified group (P = .021). Simplification to abacavir-lamivudine-zidovudine significantly decreased nonfasting cholesterol and triglyceride levels; however, this switch strategy carries a risk of virologic failure when treatment history or resistance testing suggest the presence of archived resistance mutations to the simplified regimen.
AB - This randomized study evaluated the efficacy and tolerability of continued treatment with protease inhibitor plus nucleoside-analogue combination regimens (n = 79) or a change to the simplified regimen of abacavir-lamivudine-zidovudine (n = 84) in patients with suppressed human immunodeficiency virus type 1 (HIV-1) RNA for ≥ 6 months who did not have the reverse transcriptase 215 mutation. After a median follow-up of 84 weeks, virologic failure was 6% in the continuation and 15% in the simplified group (P = .081). Previous zidovudine monotherapy or dual therapy and archived reverse transcriptase resistance mutations in HIV-1 DNA at baseline were significant predictors of failure. Study treatment was discontinued because of adverse events in 20% of the continuation and 7% of the simplified group (P = .021). Simplification to abacavir-lamivudine-zidovudine significantly decreased nonfasting cholesterol and triglyceride levels; however, this switch strategy carries a risk of virologic failure when treatment history or resistance testing suggest the presence of archived resistance mutations to the simplified regimen.
UR - http://www.scopus.com/inward/record.url?scp=0036569234&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036569234&partnerID=8YFLogxK
U2 - 10.1086/340312
DO - 10.1086/340312
M3 - Article
C2 - 12001042
AN - SCOPUS:0036569234
VL - 185
SP - 1251
EP - 1260
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 9
ER -